MiNK Therapeutics Reports agenT-797 Produces Context-Dependent Immune Responses in Cancer and ARDS

MiNK Therapeutics announced clinical findings at the American Society of Gene and Cell Therapy Annual Meeting in Boston showing that its allogeneic invariant natural killer T cell therapy produces disease-appropriate immune responses depending on the patient's condition.

The therapy, agenT-797, drove a TH1 pro-inflammatory immune program in patients with solid tumors and a TH2 anti-inflammatory response in patients with acute respiratory distress syndrome. The same product, manufactured from a single donor batch without genetic modification, was used across both groups.

Data from 34 patients with solid tumors included tumor responses with one case of complete metastatic remission. In 20 patients with ARDS, the treatment was associated with improved survival and pathogen clearance.

The findings were consistent across multiple manufacturing batches and donors. This supports the reproducibility of the manufacturing process at scale for a broadly deployable cell therapy. The results underscore the intrinsic biology of iNKT cells, which allows the same therapy to generate context-dependent effects without disease-specific engineering.

The company stated this approach enables expansion into multiple disease indications from one product.

The data support advancement into a randomized Phase 2 trial in acute lung injury, identified as study C-1300-02. Preliminary data from that trial are expected in 2026. The poster presenting the findings, numbered 3371, is scheduled for May 14, 2026.

>The same off-the-shelf cell product from one donor batch produced fundamentally different, disease-appropriate immune responses in cancer and ARDS patients.